NASDAQ: VRDN
Viridian Therapeutics Inc Stock Ownership - Who owns Viridian Therapeutics?

Insider buying vs selling

Have Viridian Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Jennifer TousignantChief Legal Officer2025-12-312,272$31.16
$70.80kSell
Fairmount Funds Management LLCDirector2025-10-23454,545$22.00
$10.00MBuy
Fairmount Funds Management LLCDirector2025-06-1012,500$12.31
$153.88kBuy
Fairmount Funds Management LLCDirector2025-06-091,600$7.80
$12.48kBuy

1 of 1

VRDN insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when VRDN insiders and whales buy or sell their stock.

VRDN Shareholders

What type of owners hold Viridian Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Fmr LLC12.83%12,249,355$404.23MInstitution
Logos Global Master Fund LP6.29%6,000,000$198.00MInsider
Blackrock Inc5.69%5,428,521$179.14MInstitution
Deep Track Capital LP5.64%5,380,449$177.55MInstitution
Fairmount Funds Management LLC4.65%4,440,851$146.55MInsider
Kynam Capital Management LP4.64%4,427,927$146.12MInstitution
Vanguard Group Inc4.54%4,331,983$142.96MInstitution
Vr Adviser LLC4.07%3,882,709$128.13MInstitution
Fairmount Funds Management LLC3.63%3,459,913$114.18MInstitution
Commodore Capital LP3.35%3,200,000$105.60MInstitution

1 of 3

VRDN vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
VRDN74.98%25.02%Net BuyingNet Selling
LEGN22.65%0.00%
XENE97.16%2.84%Net SellingNet Selling
ARQT76.71%23.29%Net SellingNet Selling
CPRX84.02%15.89%Net SellingNet Selling

Viridian Therapeutics Stock Ownership FAQ

Who owns Viridian Therapeutics?

Viridian Therapeutics (NASDAQ: VRDN) is owned by 97.66% institutional shareholders, 32.59% Viridian Therapeutics insiders, and 0.00% retail investors. Logos Global Master Fund LP is the largest individual Viridian Therapeutics shareholder, owning 6.00M shares representing 6.29% of the company. Logos Global Master Fund LP's Viridian Therapeutics shares are currently valued at $199.20M.

If you're new to stock investing, here's how to buy Viridian Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.